FindTrial
Sign In

Aluminum hydroxide

BIOLOGICAL19 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), VaxGen, National Center for Research Resources (NCRR), MedImmune LLC, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions

Coronavirus (SARS-CoV)HIV InfectionsHIV SeronegativityHIV/AIDSHealthyInfluenzaRenal FailureToxic Shock Syndrome Staphylococcal

Phase 1

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
CompletedNCT00001042
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1996-03-31Updated: 2021-11-04
A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3
CompletedNCT00000779
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1996-09-30Target: 130Updated: 2021-11-04
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.
CompletedNCT00001044
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1995-05-31Updated: 2021-11-04
A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines
CompletedNCT00002402
VaxGenHIV Infections
Target: 120Updated: 2005-06-24
A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers
CompletedNCT00000868
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, HIV Seronegativity
End: 2000-05-31Target: 27Updated: 2021-10-28
Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
WithdrawnNCT00000809
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, HIV Seronegativity
Updated: 2021-10-29
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
CompletedNCT00001052
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1997-09-30Updated: 2021-11-04
A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects
CompletedNCT00001053
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1996-03-31Updated: 2021-11-04
Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive
CompletedNCT00263744
MedImmune LLCHealthy
Start: 1999-11-30End: 2001-06-30Updated: 2009-01-08
H5 Adult - Chiron Study of Bird Flu Vaccine
CompletedNCT00280033
National Institute of Allergy and Infectious Diseases (NIAID)Influenza
Start: 2006-02-28End: 2006-11-30Updated: 2013-09-13
H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults
CompletedNCT00294099
National Institute of Allergy and Infectious Diseases (NIAID)Influenza
Start: 2006-03-31End: 2007-03-31Updated: 2013-06-03
H5 Vaccine Alone or With Adjuvant in Healthy Adults
CompletedNCT00296634
National Institute of Allergy and Infectious Diseases (NIAID)Influenza
Start: 2006-03-31End: 2006-12-31Updated: 2010-08-27
Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults
CompletedNCT00382980
National Institute of Allergy and Infectious Diseases (NIAID)Influenza
Start: 2006-10-31End: 2007-09-30Updated: 2010-08-27
SARS Coronavirus Vaccine (SARS-CoV)
WithdrawnNCT00533741
National Institute of Allergy and Infectious Diseases (NIAID)Coronavirus (SARS-CoV)
End: 2012-01-31Updated: 2012-12-03
Phase I STEBVax in Healthy Adults
CompletedNCT00974935
National Institute of Allergy and Infectious Diseases (NIAID)Toxic Shock Syndrome Staphylococcal
Start: 2011-02-28End: 2015-03-31Updated: 2015-06-19
Brilliant-001
Active, not recruitingPACTR202502617314127
South African Medical Research CouncilHIV/AIDS
Start: 2024-12-02Target: 48Updated: 2026-01-27

Phase 2

Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
CompletedNCT00529399
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Type 1 Diabetes Mellitus
Start: 2009-02-28End: 2012-05-31Updated: 2020-05-07

Unknown Phase

Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals
CompletedNCT00018135
National Center for Research Resources (NCRR)Renal Failure
Updated: 2005-06-24
The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in Monkeys
CompletedNCT00031109
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 2005-05-31Target: 10Updated: 2021-10-15

Related Papers

Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax
Clinical and Vaccine Immunology2016-10-0649 citations
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
2011-06-27276 citations
Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.
2008-11-0160 citations
Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.
2008-03-01164 citations